Literature DB >> 20956548

Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion?

Steven J R Meex1, Ursula Andreo, Janet D Sparks, Edward A Fisher.   

Abstract

Apolipoprotein-B100 (apoB100) is the essential protein for the assembly and secretion of very low density lipoproteins (VLDL) from liver. The hepatoma HepG2 cell line has been the cell line of choice for the study of synthesis and secretion of human apoB-100. Despite the general use of HepG2 cells to study apoB100 metabolism, they secrete relatively dense, lipid-poor particles compared with VLDL secreted in vivo. Recently, Huh-7 cells were adopted as an alternative model to HepG2 cells, with the implicit assumption that Huh-7 cells were superior in some respects of lipoprotein metabolism, including VLDL secretion. In this study we addressed the hypothesis that the spectrum of apoB100 lipoprotein particles secreted by Huh-7 cells more closely resembles the native state in human liver. We find that Huh-7 cells resemble HepG2 cells in the effects of exogenous lipids, microsomal triglyceride transfer protein (MTP)-inhibition, and proteasome inhibitors of apoB100 secretion, recovery, and degradation. In contrast to HepG2 cells, however, MEK-ERK inhibition does not correct the defect in VLDL secretion. Huh-7 cells do not appear to offer any advantages over HepG2 cells as a general model of human apoB100-lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956548      PMCID: PMC2999930          DOI: 10.1194/jlr.D008888

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  21 in total

1.  The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70.

Authors:  E A Fisher; M Zhou; D M Mitchell; X Wu; S Omura; H Wang; A L Goldberg; H N Ginsberg
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein.

Authors:  F Benoist; T Grand-Perret
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

3.  Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B.

Authors:  S J Yeung; S H Chen; L Chan
Journal:  Biochemistry       Date:  1996-10-29       Impact factor: 3.162

4.  Regulated Co-translational ubiquitination of apolipoprotein B100. A new paradigm for proteasomal degradation of a secretory protein.

Authors:  M Zhou; E A Fisher; H N Ginsberg
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

5.  Myristic acid increases dense lipoprotein secretion by inhibiting apoB degradation and triglyceride recruitment.

Authors:  Emma Kummrow; M Mahmood Hussain; Meihui Pan; Julian B Marsh; Edward A Fisher
Journal:  J Lipid Res       Date:  2002-12       Impact factor: 5.922

6.  Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.

Authors:  Florent Lalanne; Gilles Lambert; Marcelo J A Amar; Maud Chétiveaux; Yassine Zaïr; Anne-Laure Jarnoux; Khadija Ouguerram; José Friburg; Nabil G Seidah; H Bryan Brewer; Michel Krempf; Philippe Costet
Journal:  J Lipid Res       Date:  2005-03-01       Impact factor: 5.922

7.  The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100.

Authors:  Christopher Cardozo; Xinye Wu; Meihui Pan; Hongxing Wang; Edward A Fisher
Journal:  Biochemistry       Date:  2002-08-06       Impact factor: 3.162

8.  Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence.

Authors:  D M Mitchell; M Zhou; R Pariyarath; H Wang; J D Aitchison; H N Ginsberg; E A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits.

Authors:  J R Wetterau; R E Gregg; T W Harrity; C Arbeeny; M Cap; F Connolly; C H Chu; R J George; D A Gordon; H Jamil; K G Jolibois; L K Kunselman; S J Lan; T J Maccagnan; B Ricci; M Yan; D Young; Y Chen; O M Fryszman; J V Logan; C L Musial; M A Poss; J A Robl; L M Simpkins; W A Slusarchyk; R Sulsky; P Taunk; D R Magnin; J A Tino; R M Lawrence; J K Dickson; S A Biller
Journal:  Science       Date:  1998-10-23       Impact factor: 47.728

10.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Authors:  Meihui Pan; Arthur I Cederbaum; Yuan-Li Zhang; Henry N Ginsberg; Kevin Jon Williams; Edward A Fisher
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

View more
  53 in total

Review 1.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

2.  Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100.

Authors:  Jaume Amengual; Liang Guo; Alanna Strong; Julio Madrigal-Matute; Haizhen Wang; Susmita Kaushik; Jeffrey L Brodsky; Daniel J Rader; Ana Maria Cuervo; Edward A Fisher
Journal:  Circ Res       Date:  2018-01-04       Impact factor: 17.367

3.  Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33.

Authors:  Ryan M Allen; Tyler J Marquart; Jordan J Jesse; Angel Baldán
Journal:  Circ Res       Date:  2014-04-21       Impact factor: 17.367

4.  PNPLA2 influences secretion of triglyceride-rich lipoproteins by human hepatoma cells.

Authors:  Apostolos Taxiarchis; Hovsep Mahdessian; Angela Silveira; Rachel M Fisher; Ferdinand M Van't Hooft
Journal:  J Lipid Res       Date:  2019-03-27       Impact factor: 5.922

5.  A conserved RNA structural element within the hepatitis B virus post-transcriptional regulatory element enhance nuclear export of intronless transcripts and repress the splicing mechanism.

Authors:  Akasit Visootsat; Sunchai Payungporn; Nattanan P T-Thienprasert
Journal:  Mol Biol Rep       Date:  2015-10-29       Impact factor: 2.316

6.  The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles.

Authors:  Audrey Boyer; Amélie Dumans; Elodie Beaumont; Loïc Etienne; Philippe Roingeard; Jean-Christophe Meunier
Journal:  J Biol Chem       Date:  2014-05-16       Impact factor: 5.157

Review 7.  The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways.

Authors:  Edward A Fisher
Journal:  Biochim Biophys Acta       Date:  2012-02-10

8.  Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Authors:  Koen Vercauteren; Naomi Van Den Eede; Ahmed Atef Mesalam; Sandrine Belouzard; Maria Teresa Catanese; Dorothea Bankwitz; Flossie Wong-Staal; Riccardo Cortese; Jean Dubuisson; Charles M Rice; Thomas Pietschmann; Geert Leroux-Roels; Alfredo Nicosia; Philip Meuleman
Journal:  Hepatology       Date:  2014-07-30       Impact factor: 17.425

9.  Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.

Authors:  Baptiste Jammart; Maud Michelet; Eve-Isabelle Pécheur; Romain Parent; Birke Bartosch; Fabien Zoulim; David Durantel
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

10.  Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.

Authors:  Sara Calattini; Floriane Fusil; Jimmy Mancip; Viet Loan Dao Thi; Christelle Granier; Nicolas Gadot; Jean-Yves Scoazec; Mirjam B Zeisel; Thomas F Baumert; Dimitri Lavillette; Marlène Dreux; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2015-07-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.